ABSTRACT
Understanding the cellular underpinnings of neurodegeneration remains a challenge; loss of synapses and dendritic arborisation are characteristic and can be quantified in vivo, with [11C]UCB-J PET and MRI-based Orientation Dispersion Imaging (ODI), respectively. We aimed to assess how both measures are correlated, in 4R-tauopathies of Progressive Supranuclear Palsy (PSP-RS; n = 22) and amyloid-negative (determined by [11C]PiB PET) Corticobasal Degeneration (CBD; n =14), as neurodegenerative disease models, in this proof-of-concept study. Compared to controls (n = 27), PSP-RS and CBD patients had widespread reductions in cortical ODI, and [11C]UCB-J non-displaceable binding potential (BPND) in excess of atrophy. In PSP-RS and CBD separately, regional cortical ODI was significantly associated with [11C]UCB-J BPND in disease-associated regions (p < 0.05, FDR corrected). Our findings indicate that reductions in synaptic density and dendritic complexity in PSP-RS and CBD are more severe and extensive than atrophy. Furthermore, both measures are tightly coupled in vivo, furthering our understanding of the pathophysiology of neurodegeneration, and applicable to studies of early neurodegeneration with a safe and widely available MRI platform.
Competing Interest Statement
James B Rowe serves as an associate editor to Brain and is a non-remunerated trustee of the Guarantors of Brain, Darwin College and the PSP-RS Association (UK). He provides consultancy to Asceneuron, Biogen, UCB, Althira, Astex, SVHealth and has research grants from AZ-Medimmune, Janssen, Lilly as industry partners in the Dementias Platform UK. John T. O ,Brien has no conflicts related to this study - unrelated to this work he has received honoraria for work as DSMB chair or member for TauRx, Axon, Eisai, has acted as a consultant for Roche, has received research support from Alliance Medical and Merck.
Funding Statement
The study was funded by the Cambridge University Centre for Parkinson-Plus (RG95450); the National Institute for Health Research Cambridge Biomedical Research Centre (146281); the Wellcome Trust (103838) and the Association of British Neurologists; Patrick Berthoud Charitable Trust (NH RG99368). EM is supported by Alzheimer ,s Society Junior Research Fellowship (443 AS JF 18017). RRG is supported by the Guarantors of Brain Fellowship (RNAG/474). AL is supported by the Lee Kuan Yew Fitzwilliam Scholarship and the Tan Kah Kee Scholarship. TR has received honoraria from Biogen and the National Institute for Health and Clinical Excellence (NICE).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research protocol was approved by the Cambridge Research Ethics Committee and the Administration of Radioactive Substances Advisory Committee. All participants provided written informed consent in accordance with the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author, upon reasonable request for academic (non-commercial) purposes, subject to restrictions required to preserve participant confidentiality.
Abbreviations
- PSP-RS
- Progressive Supranuclear Palsy – Richardson’s Syndrome.
- CBD
- Corticobasal degeneration
- PET
- Positron Emission Tomography
- NODDI
- Neurite Orientation and Dispersion Imaging.
